Related references
Note: Only part of the references are listed.Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy
Whitney B. Pope et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2011)
Clinical trial end points for high-grade glioma: the evolving landscape
David A. Reardon et al.
NEURO-ONCOLOGY (2011)
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
W. B. Pope et al.
NEUROLOGY (2011)
Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis
Jennifer C. Kesselheim et al.
ONCOLOGIST (2011)
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis
Tao Xu et al.
BMC CANCER (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
Richard M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
John F. de Groot et al.
NEURO-ONCOLOGY (2010)
Pseudoprogression and pseudoresponse in the treatment of gliomas
Dieta Brandsma et al.
CURRENT OPINION IN NEUROLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods
E Galanis et al.
NEURO-ONCOLOGY (2006)
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas
GD Shah et al.
NEURO-ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
